Risk adjusted net present value: What is the current valuation of Moderna’s MRNA-0184?
Pharmaceutical Technology
JUNE 6, 2023
The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. MRNA-0184 Overview mRNA-0184 is under development for the treatment decompensated heart failure. The therapeutic candidate consists of messenger RNA (mRNA) encoding for relaxin.
Let's personalize your content